Ivonescimab + chemo shows OS benefit in EGFRm NSCLC; HR 0.74 in HARMONi-A final analysis

Summit Therapeutics Inc.

Final OS analysis: ivonescimab+chemo vs chemo achieved HR 0.74 (95% CI: 0.58-0.95, p=0.019); median OS 16.8 vs 14.1 months.
First Phase III study of ivonescimab to show statistically significant OS benefit; prior HARMONi showed PFS benefit.
Over 40,000 patients treated with ivonescimab in China in clinical/commercial settings.
Safety manageable: TRAE discontinuation 11.2% vs 6.2%; no additional TRAE deaths vs chemo alone.
Global HARMONi study subsequent OS analysis: HR 0.78 (nominal p=0.0332) consistent with primary HR 0.79.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.